Page 23 - Gene Therapy Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 29, 2021-- The international rare disease patient advocacy organization, Global Genes, is pleased to announce the 6th Annual RARE Drug Development Symposium (RDDS) in partnership with the Orphan Disease Center of the University of Pennsylvania. The June 9-11 virtual event will connect and educate hundreds of advocates, clinicians, and academic and industry researchers to explore the latest science, opportunities, and challenges to the advancement of therapies for more than 7,000 rare diseases. New to this year's event is an optional preconference work...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Aruvant Announces Oral Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting April 27, 2021 GMT (PRNewsfoto/Aruvant Sciences) NEW YORK and BASEL, Switzerland, April 27, 2021 /PRNewswire/ -- Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, today announced that data on ARU-1801, a potentially curative gene therapy for sickle cell disease (SCD), will be delivered in an oral presentation at the American Society of...

Taysha Gene Therapies Inc (NASDAQ: TSHA) Regeneron Pharmaceuticals Inc (NASDAQ: REGN)Moderna Inc Moderna is an mRNA vaccine company that has been one of the biggest winners in the healthcare sector. The company is one of the first in the world to receive the Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its coronavirus vaccine. In addition, its mRNA science is also contributing to the development of new drugs in the foreseeable future. For example, Moderna is developing therapeutics for infectious diseases, immuno-oncology, and cardiovascular diseases....

- Urgency for effective treatment underscored by European Commission designation for investigational gene therapy PBKR03 - Global Phase 1/2 trial – GALax-C – PBKR03 planned to initiate in first half of 2021 PHILADELPHIA, April 05, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that the European Commission has granted Orphan designation for PBKR03, an adeno-associated virus (AAV)-delivery gene therapy for the trea...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Scout Bio to Present at the BofA Securities 2021 Animal Health Summit Scout BioFebruary 18, 2021 GMT PHILADELPHIA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Scout Bio, a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions, today announced that Mark Heffernan, Scout Bio’s Chief Executive Officer, will present at the upcoming BofA Securities 2021 Animal Health Summit on Thursday, February 25, 2021 at 2:35 p.m. ET. A...